Evaluation of Efficacy and Safety of PD-1 Monoclonal Antibody in Combination With rhG-CSF, IL-2, and CapeOX in Initially Resectable Synchronous Colorectal Liver Metastases: A Single-Center, Single-Arm, Open-Label Clinical Study (PRICE)

This study attempts to employ a combination therapy using rhG-CSF, IL-2, and PD-1 inhibitors, aiming to overcome the limitations of monotherapy in immunotherapy through multi-faceted immune regulation. By modulating the immune microenvironment to enhance immune cell infiltration, and breaking through the physical and immunosuppressive barriers of tumors, it seeks to augment the efficacy of immunotherapy. This approach explores the effectiveness of a neoadjuvant treatment model in cases of liver metastasis.

开始日期2024-07-10

申办/合作机构

常州市第二人民医院

EUCTR2019-001696-36-IT / Not yet recruiting临床2期IIT

Study of efficacy of low-dose recombinant human interleukin-2 in immunological changes associated with depression (IL2REG) - IL2REG

开始日期2019-10-09

申办/合作机构

Ospedale San Raffaele Srl

NCT02467504 / Completed临床2期IIT

A Randomized, Double Blind, Placebo-controlled Pilot-study to Evaluate Efficacy and Safety of Low-dose hrIL-2 in the Treatment of Methotrexate (MTX)-Naive Patients With Rheumatoid Arthritis

Rheumatoid arthritis (RA) is an immune-mediated inflammatory disease, characterized by symmetric poly-arthritis usually involving the small joints of the hands and feet. In addition, various extra-joint manifestations may develop. Several immunomodulating agents have been attempted in the treatment of RA without achieving satisfactory results. Dysfunction of regulatory T (Treg) cells has been detected in diverse autoimmune diseases, which can be promoted by interleukin-2 (IL-2). The investigators hypothesized that low-dose IL-2 could be a novel therapy in active RA patients. This clinical study will test the efficacy and safety of low dose IL-2 treatment in RA. The investigators perform a single-centre, double-blind pilot trial with hrIL-2 in RA. The investigators evaluate the effectiveness and safeness of low-dose hrIL-2 for RA by randomized controlled study (hrIL-2 (N = 23) + Methotrexate (MTX)+ Loxoprofen versus placebo+MTX + Loxoprofen group (N = 24)).

开始日期2015-07-01

申办/合作机构

北京大学人民医院

[+2]

100 项与重组人白介素-2 (北京双鹭药业) 相关的临床结果

登录后查看更多信息

100 项与重组人白介素-2 (北京双鹭药业) 相关的转化医学

登录后查看更多信息

100 项与重组人白介素-2 (北京双鹭药业) 相关的专利（医药）

登录后查看更多信息

100 项与重组人白介素-2 (北京双鹭药业) 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	-	L03AC01	-

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
肿瘤	中国	北京双鹭药业股份有限公司	1999-01-01

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
原发性干燥综合征	临床2期	中国	北京双鹭药业股份有限公司	2015-06-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT02467504 (CTgov)	临床2期	类风湿关节炎	47	Loxoprofen+Folic Acid+MTX+hrIL-2 active (Experimental)	壓鏇觸網淵鹹壓夢顧遞(遞壓醖廠鹽遞糧範鏇積) = 艱淵艱範膚蓋願鹹醖顧鏇鏇鹹觸積遞壓簾願鬱 (願艱選糧齋蓋衊廠網蓋, 糧醖願網衊艱願糧繭繭 ~ 製糧願遞範鹽餘廠餘獵) 更多	-	2019-09-09
				hrIL-2 placebo+Loxoprofen+Folic Acid+MTX (Placebo Comparator)	壓鏇觸網淵鹹壓夢顧遞(遞壓醖廠鹽遞糧範鏇積) = 鑰鹽餘築選積壓築醖獵鏇鏇鹹觸積遞壓簾願鬱 (願艱選糧齋蓋衊廠網蓋, 憲襯廠選構齋繭簾醖衊 ~ 淵餘餘衊鬱網壓憲鹽築) 更多